PACE (Pathways to Antimicrobial Clinical Efficacy) is one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery. PACE helps to fast-track the most promising antimicrobial innovations by providing essential resources and support, maximizing the chances of success in the fight against antimicrobial resistance (AMR).
PhalconBio, a Swiss biotech company, is committed to delivering ground-breaking precision medicines to address critical challenges in AMR and beyond. By leveraging its proprietary engineered-phage platform, the company is tackling multidrug-resistant infections with innovative, phage-based therapeutic solutions. PACE has announced PhalconBio as one of the awardees of its £10m antimicrobial therapeutics funding call. Through funding and support, PACE will help PhalconBio in the development of engineered phage therapies targeting lower respiratory tract infections caused by multidrug-resistant Pseudomonas aeruginosa.
